The Turkish trials found that China’s Sinovac inoculation is 83.5% effective against the coronavirus, a level of protection that is lower than the country’s initial predictions but significantly above Brazilian estimates.
CoronaVac’s photo taken by Sinovac Biotech Ltd. was 100% effective in preventing hospitalization, according to phase 3 trials at the prestigious Hacettepe University in Ankara, the state agency Anadolu reported.
Turkey has been conducting trials of the vaccine since September, and initial findings suggested an efficacy rate of 91.25%, the Ministry of Health said. announced in late December.
The Chinese vaccine has provided highly variable efficacy rates at four clinical trial sites, raising concerns about whether the vaccine will be effective in stopping outbreaks in the countries where it is administered.
Brazilian officials have said that the CoronaVac injection was 50.38% effective in preventing coronavirus cases, a number that meets the threshold required by global regulators for approval, but is well below the previous 78 assessment. % from the country.
Sinovac defended its product in January, saying that despite inconsistent data readings, the vaccine is more effective at preventing disease if the two-dose regimen is given over a longer period of time.
Sinovac Reports Phase 3 Results of Covid-19 Vaccine Study
Turkey has a agreed to buy 100 million doses of the Sinovac vaccine, and began inoculating citizens in January, as it has sought to lift restrictions on its economy.
CoronaVac was preferred because it was found to be the safest, as it was manufactured using conventional methods, Turkish Health Minister Fahrettin Koca has repeatedly said. However, Turkey has also signed an agreement for 4.5 million doses of the vaccine produced by Pfizer Inc. and BioNTech SE, and said it is in talks with AstraZeneca Plc to obtain supplies for its injection.